PT2376101E - Efectores da beta-arrestina e composições e métodos para a sua utilização - Google Patents

Efectores da beta-arrestina e composições e métodos para a sua utilização Download PDF

Info

Publication number
PT2376101E
PT2376101E PT98365208T PT09836520T PT2376101E PT 2376101 E PT2376101 E PT 2376101E PT 98365208 T PT98365208 T PT 98365208T PT 09836520 T PT09836520 T PT 09836520T PT 2376101 E PT2376101 E PT 2376101E
Authority
PT
Portugal
Prior art keywords
beta
compositions
methods
arrestin effectors
arrestin
Prior art date
Application number
PT98365208T
Other languages
English (en)
Inventor
Dennis Yamashita
Xiao-Tao Chen
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of PT2376101E publication Critical patent/PT2376101E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT98365208T 2008-12-29 2009-12-28 Efectores da beta-arrestina e composições e métodos para a sua utilização PT2376101E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14112608P 2008-12-29 2008-12-29

Publications (1)

Publication Number Publication Date
PT2376101E true PT2376101E (pt) 2016-02-04

Family

ID=42310455

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98365208T PT2376101E (pt) 2008-12-29 2009-12-28 Efectores da beta-arrestina e composições e métodos para a sua utilização

Country Status (17)

Country Link
US (7) US8486885B2 (pt)
EP (1) EP2376101B1 (pt)
JP (1) JP5647146B2 (pt)
CN (1) CN102333536B (pt)
AU (1) AU2009333883B2 (pt)
CA (1) CA2748340C (pt)
CY (1) CY1117184T1 (pt)
DK (1) DK2376101T3 (pt)
ES (1) ES2558629T3 (pt)
HK (1) HK1162955A1 (pt)
HR (1) HRP20151440T1 (pt)
HU (1) HUE026131T2 (pt)
NZ (1) NZ594302A (pt)
PL (1) PL2376101T3 (pt)
PT (1) PT2376101E (pt)
SI (1) SI2376101T1 (pt)
WO (1) WO2010077339A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376101B1 (en) 2008-12-29 2015-12-02 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
CN104168907A (zh) 2012-01-31 2014-11-26 特维娜有限公司 β-抑制蛋白效应器及其组合物与使用方法
JP2017506235A (ja) 2014-02-07 2017-03-02 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． ベータ−アレスチンエフェクターの結晶性および非晶質形態
AU2015264367A1 (en) 2014-05-19 2016-12-15 Trevena, Inc. Synthesis of Beta-Arrestin Effectors
CN104162146B (zh) * 2014-08-06 2016-12-07 中国人民解放军第二军医大学 β-抑制蛋白-1在制备预防或治疗心梗药物中的应用
WO2016196750A1 (en) * 2015-06-03 2016-12-08 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
JOP20170133B1 (ar) * 2016-06-02 2022-03-14 Ferring Bv عوامل مضادة لمستقبل أنجيوتنسين-1
TWI776812B (zh) 2016-06-02 2022-09-11 荷蘭商菲林公司 血管收縮素-1-受體拮抗劑
EA039493B1 (ru) 2016-06-29 2022-02-02 Университе Де Монреаль Биарилметильные гетероциклы
WO2021216529A1 (en) * 2020-04-21 2021-10-28 Trevena, Inc. β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751404A (en) 1971-02-12 1973-08-07 Morton Norwich Products Inc L-prolyl-l-arginyl-l-volyl-l-tyrosyl-l-volyl-l-histidyl-l-prolyl-glycine
DE2360794C2 (de) 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
US3932624A (en) * 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4298523A (en) 1980-06-17 1981-11-03 Ortho Pharmaceutical Corporation Methods and compositions for preparation of H-ARG-X-Z-Y-TYR-R
US4547489A (en) 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
DE68903907T2 (de) 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
GB8822483D0 (en) * 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
CA2090401A1 (en) 1990-08-27 1992-02-28 Deborah A. Rathjen Method of treating viral infection
AU1256692A (en) 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
ES2168312T3 (es) 1993-09-24 2002-06-16 Univ Southern California Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
CA2181461A1 (en) * 1994-02-08 1995-08-17 Alica Huxley Treatment of normotensive glaucoma with angiotensin ii antagonists
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
WO1999031125A1 (en) * 1997-12-12 1999-06-24 University Of Southern California Wound healing compositions
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20050202029A1 (en) 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
CA2692372A1 (en) 2007-06-27 2008-12-31 Clayton Corporation Dispensing system and method of use
US20110190373A1 (en) 2008-05-05 2011-08-04 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
US8038992B2 (en) 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
EP2376101B1 (en) 2008-12-29 2015-12-02 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
WO2012150890A1 (en) 2011-05-02 2012-11-08 Lipidor Ab Antibacterial composition

Also Published As

Publication number Publication date
US8809260B2 (en) 2014-08-19
HRP20151440T1 (hr) 2016-01-29
US8486885B2 (en) 2013-07-16
JP2012514033A (ja) 2012-06-21
DK2376101T3 (en) 2016-01-18
ES2558629T3 (es) 2016-02-05
US20130274176A1 (en) 2013-10-17
CN102333536B (zh) 2014-08-13
US8796204B2 (en) 2014-08-05
HK1162955A1 (zh) 2012-09-07
US8993511B2 (en) 2015-03-31
CN102333536A (zh) 2012-01-25
NZ594302A (en) 2013-07-26
HUE026131T2 (en) 2016-05-30
CA2748340C (en) 2017-01-24
JP5647146B2 (ja) 2014-12-24
US20150166604A1 (en) 2015-06-18
US20100184701A1 (en) 2010-07-22
CA2748340A1 (en) 2010-07-08
EP2376101A2 (en) 2011-10-19
US20140336123A1 (en) 2014-11-13
AU2009333883A1 (en) 2011-08-18
EP2376101B1 (en) 2015-12-02
AU2009333883B2 (en) 2015-05-21
US20170298094A1 (en) 2017-10-19
SI2376101T1 (sl) 2016-02-29
US20140357562A1 (en) 2014-12-04
PL2376101T3 (pl) 2016-03-31
WO2010077339A3 (en) 2011-02-24
WO2010077339A2 (en) 2010-07-08
US20140005114A1 (en) 2014-01-02
EP2376101A4 (en) 2012-11-28
US9534017B2 (en) 2017-01-03
CY1117184T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
PL2376101T3 (pl) Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania
EP2364161A4 (en) COMPOSITIONS CONTAINING SATIOGENES AND METHODS OF USE
IL208946A0 (en) Immunomodulating compositions and methods of use thereof
HK1144319A1 (en) Compositions and methods of detecting tiabs
EP2320911A4 (en) VESSEL SUSPENSION COMPOSITIONS AND METHOD FOR THEIR USE
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
PL2346327T3 (pl) Kompozycje biobójcze i sposoby stosowania
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
HK1149933A1 (en) Diazacarbazoles and methods of use
IL208403A0 (en) Compositions and use of epas1 inhibitors
IL209548A0 (en) Diazacarbazoles and methods of use
EP2134352A4 (en) WNT COMPOSITIONS AND METHODS FOR THEIR USE
EP2421901A4 (en) COMPOSITION CONTAINING THE HC HA COMPLEX AND METHODS OF USE THEREOF
EP2271750A4 (en) URICASE COMPOSITIONS AND METHODS OF USE
HK1140019A1 (en) Compositions and methods of detection
PL2179657T3 (pl) Kompozycje z efuzją gazu i sposób ich wytwarzania
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
EP2416796A4 (en) Modified dnase compositions and methods of use thereof
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
ZA201004894B (en) Nuctraceutical composition and methods of use
HK1166953A1 (en) Compositions and methods of use
ZA201004893B (en) Nuctraceutical composition and methods of use
PL2128112T3 (pl) Cząsteczkowe kompozycje odpowietrzające i sposoby ich stosowania